Table 1

Characteristics of the study cohorts in the primary study period 1998–2014 and in the sensitivity analysis study period 1987–2014

Follow-up 1998–2014Follow-up 1987–2014
Patients with NF1ControlsSiblings without NF1Patients with NF1ControlsSiblings without NF1
n134913 8701871141014 0171881
Sex
 Females, n (%)694 (51.4)7189 (51.8)893 (47.7)732 (51.9)7256 (51.8)895 (47.6)
 Males, n (%)655 (48.6)6681 (48.2)978 (52.3)678 (48.1)6761 (48.2)986 (52.4)
Year of birth, mean (SD)1975.2 (21.6)1974.4 (22.0)1976.5 (18.5)1974.0 (22.4)1974.0 (22.4)1976.4 (18.5)
Start of follow-up (cohort entry)
 Age, mean (SD)25.7 (20.7)26.3 (21.0)24.4 (17.4)23.6 (20.7)23.6 (20.7)21.5 (16.7)
 Year, mean (SD)2001.1 (4.2)2001.0 (4.1)2001.1 (4.1)1997.6 (7.3)1997.6 (7.3)1997.9 (7.2)
End of follow-up
 Age, mean (SD)38.3 (20.8)39.7 (21.5)37.8 (18.4)38.6 (21.0)40.0 (21.6)37.7 (18.4)
 Year, mean (SD)2013.1 (2.8)2013.7 (1.8)2013.7 (1.5)2012.2 (4.9)2013.5 (2.7)2013.6 (2.1)
Follow-up time, mean (SD)12.7 (4.9)13.4 (4.5)13.4 (4.4)15.0 (7.5)16.3 (7.4)16.2 (7.2)
  • NF1, neurofibromatosis type 1.